Gary Bird has been appointed Chief Executive Officer of LumaCina, a Perth-based supplier of sterile injectable pharmaceuticals and a portfolio company of Miami-based Bridgewest Group. The appointment, announced July 14, was made by Executive Chair Mark Crotty, who will continue overseeing long-term strategy and platform development alongside Bird. The move marks LumaCina's next phase of expansion as it seeks to establish itself as a global competitor in the tightly regulated market for hospital-grade injectable medicines.
Bird brings more than three decades of pharmaceutical industry experience in Australia and the Asia-Pacific region, having held senior leadership roles at Johnson & Johnson, Sanofi-Aventis, and Pharmacia earlier in his career. Most recently, over the past 13 years, he has led or represented companies including Orion Pharma, Medreich, and Meda, working across pharmaceutical distribution, contract manufacturing, specialty medicines, and consumer healthcare. He holds a Medical Science degree from the University of Sydney and is a graduate of the Asialink Business Leaders Program at the University of Melbourne. Bird previously served as a board member of Heartkids Australia and as a local councillor in Hunters Hill, New South Wales. According to Crotty, Bird's combination of deep pharmaceutical expertise and proven ability to build commercial partnerships made him "the outstanding choice to lead the business." Bird had already engaged with LumaCina's leadership team during strategic planning processes prior to his formal appointment, giving him visibility into operations, customer relationships, and corporate priorities.
LumaCina operates a 34,000-square-metre manufacturing facility in Bentley, Perth, employing over 400 staff across nine production lines capable of manufacturing high-potency injectables, oncology drugs, blow-fill-seal formulations, and multi-format vials. The company currently supplies sterile injectable pharmaceutical products to customers across Australia, New Zealand, Asia, and Northern Europe. The facility has a 30-year history producing quality injectables and is one of Australia's most advanced sterile injectable plants, holding regulatory approvals from the FDA, TGA, and EMA. Bridgewest Group acquired the facility from Pfizer in 2023 and established LumaCina as a separate operating unit later that year, inheriting a legacy portfolio of proven hospital medicines and a track record of supply reliability across more than 90 countries.
Bridgewest Group is a $3 billion privately held investment firm founded in 1999, with a stated focus on building and scaling transformational businesses across life sciences, software, semiconductors, and artificial intelligence. Dr. Masood Tayebi, Bridgewest's co-founder and CEO, welcomed Bird's appointment, stating that "Gary's appointment marks an important milestone in LumaCina's evolution as an independent pharmaceutical company." Tayebi noted that Crotty's work as strategic architect has created "a durable foundation for future growth," positioning the newly appointed dual leadership structure to combine continuity with deep sector expertise and commercial execution capability.
Bird's appointment signals Bridgewest's commitment to transforming LumaCina from a legacy Pfizer operation into a growth-oriented global competitor. The timing appears strategic given LumaCina's stated intent to expand its portfolio through acquisitions and licensing partnerships and to broaden its geographic presence beyond its current concentration in Australia and New Zealand, where historically 95 percent of production has remained. Bird's experience building commercial relationships across major pharmaceutical markets in Asia-Pacific and his track record developing distribution and partnership-led growth strategies align with these stated ambitions. The appointment of an externally recruited operational CEO distinct from Crotty's strategic role suggests Bridgewest intends to accelerate commercialization while maintaining long-term platform development under experienced, aligned leadership. No executive search firm involvement was disclosed in the announcement.
